TRIFECTA CELL INFUSION
Live / Applied — Suspended — suspension letter mailed (as of 17 Nov 2025)
What this means for you
Not registered yet, but its 03 Mar 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99064085
- Mark type
- Stylized text
- Filed
- 03 Mar 2025
- Attorney of record
- Michael J. McCue
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations and substances for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention and treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer; pharmaceutical preparations and substances containing autologous or allogeneic cells for the treatment of human diseases and animal diseases in the nature of cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases and infectious diseases; biologic in the nature of pharmaceutical preparations for the treatment of autoimmune diseases, infectious diseases, and cancer, namely, cell-derived preparations, cell therapies, monoclonal antibodies, cytokines, immune modulators, antibodies, fusion proteins, peptide and cytokine biologics, and natural killer cell derived preparations for clinical, medicinal, therapeutic, and veterinary purposes; kits comprising cell cultures being biological preparations for medical purposes and reagents for medical use and also including printed instructions, for use in the treatment and prevention of bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, and cancer for clinical, medicinal, therapeutic and veterinary purposes; all of the aforementioned excluding preparations and substances used in connection with implant material
Owner
- ImmunityBio, Inc., San Diego, CA, US
Prosecution history
- 17 Nov 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 17 Nov 2025 — LETTER OF SUSPENSION E-MAILED
- 17 Nov 2025 — SUSPENSION LETTER WRITTEN
- 27 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 27 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 07 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 07 Aug 2025 — NON-FINAL ACTION E-MAILED
- 07 Aug 2025 — NON-FINAL ACTION WRITTEN
- 05 Aug 2025 — ASSIGNED TO EXAMINER
- 03 Mar 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 03 Mar 2025 — APPLICATION FILING RECEIPT MAILED
- 03 Mar 2025 — NEW APPLICATION ENTERED